Market Report -- In Play (COV)
November 20, 2009 7:30 AM ET
Covidien announces that FDA Extends Review of NDA for Exalgo Co announces that the FDA has set a new action date under the Prescription Drug User Fee Act for the review of the New Drug Application for Exalgo Tablets of February 22, 2010. Neuromed Pharmaceuticals Ltd. and COV recently provided the FDA with supplemental information, which the agency determined to be a major amendment to the NDA. As a result, the FDA has extended its action date by three months to allow more time to review the application. The proposed indication for Exalgo is once daily administration for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S. Bond, and world FX market participants.
Read more In Play articles
Back to News Home
- MSN Money
- Search MSN Money
- Message Boards
- Site Status
For today's top Money video click here
E-mail this article
Print-friendly version
Discuss this article